secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001558370-24-003735
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA Pharma Q4/FY2023 net loss $24.8M/$81.6M; cash $117.5M; HB-200 ORR 42%
-----------------------------------------------------------------------------

- Net loss $24.8M (Q4) and $81.6M (FY2023), vs $12.3M and $64.9M in prior year.
- Revenue $7.4M (Q4) and $20.1M (FY2023); R&D expenses $21.2M and $86.4M.
- Cash and equivalents $117.5M at Dec 31, 2023, including $71M from capital raises and $15M in milestones.
- HB-200 + pembrolizumab showed 42% objective response rate in 1L HPV16+ HNSCC; pivotal trial to start 2024.
- Roche terminated HB-700 collaboration; HOOKIPA to regain rights; IND filing by April 2024 triggers final milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000155837024003735/0001558370-24-003735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000155837024003735/hook-20240322x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-003735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer